Skip to content


We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.

ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.

Our targeted strategy is designed to selectively protect healthy cells throughout the body without protecting cancer cells from chemotherapy. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Better tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy.

Our Mission:

To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life.

Our Vision:

To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.

Learn more about our biomarker-driven, selective chemoprotection strategy.


“All cancer patients undergoing chemotherapy – still the standard of care for most patients – experience chemotherapy-induced side effects to varying degrees, from unpleasant to fatal. Using a biomarker strategy, we are developing ALRN-6924 as a selective chemoprotection agent to shift the paradigm from accepting these side effects to preventing them for patients with p53-mutated cancer regardless of type of cancer or chemotherapy.”
Manuel C. Aivado, M.D., Ph.D
President & Chief Executive Officer

Board of Directors

In Memoriam
John H. McArthur
Former Dean and George F. Baker Professor of Administration, Emeritus
Harvard Business School
Link To Bio

Scientific Advisory Board

Brian Drucker, M.D.
Director, Knight Cancer Institute, Oregon Health and Science School of Medicine;
JELD-WEN Chair of Leukemia Research
Investigator, Howard Hughes Medical Institute
Link To Bio
In Memoriam
Robert H. Grubbs, Ph.D.
Former Victor and Elizabeth Atkins Professor of Chemistry, California Institute of Technology
Nobel Prize Laureate for Chemistry in 2005
Link To Bio Read Caltech Announcement
Alan F. List, M.D.
Chief Medical Officer, Precision Biosciences, Inc.
Former President and Chief Executive Officer, Moffitt Cancer Center
Link To Bio
Carol Prives, Ph.D.
Da Costa Professor of Biology,
Department of Biological Sciences
Columbia University
Link To Bio
Ulrich Steidl, M.D., Ph.D.
Professor, Department of Cell Biology
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine – Montefiore Medical Center
Link To Bio